| Trial ID: | L0091 |
| Source ID: | NCT05063968
|
| Associated Drug: |
XZP-6019
|
| Title: |
A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
|
| Acronym: |
--
|
| Status: |
Not yet recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: XZP-6019 tablet|Drug: Placebo
|
| Outcome Measures: |
Cmax|Tmax|AUC0-t|AUC0-inf|T1/2|CL/F|Vz/F|Subject incidence of adverse events for XZP-6019 versus placebo
|
| Sponsor/Collaborators: |
Xuanzhu Biopharmaceutical Co., Ltd.
|
| Gender: |
All
|
| Age: |
18 Years to 45 Years ?? (Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
120
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
November 30, 2021
|
| Completion Date: |
September 30, 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
October 1, 2021
|
| Locations: |
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
|
| URL: |
https://ClinicalTrials.gov/show/NCT05063968
|
